GlassScriptPhysician profile
Ankit Gulati
NPI 1902195795
$3,594.08
in general payments reported to CMS, 2019-2025
37 companies · $870 in 2025
The $870 reported for 2025 was more than what 86% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $276 · 2020: $255 · 2021: $263 · 2022: $502 · 2023: $626 · 2024: $802 · 2025: $870.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,297.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,611.27 | 2022-2025 | |
| Allergan, INC. | $349.35 | 2019-2022 | |
| Depuy Synthes Sales INC. | $238.81 | 2022-2023 | Synthecel, Matrixneuro |
| Merz Pharmaceuticals, LLC | $163.09 | 2022-2024 | Xeomin, Inbrija |
| Medtronic, INC. | $133.22 | 2021-2024 | Synchromedii |
| Pacira Therapeutics, INC. | $108.74 | 2019-2021 | |
| Baxter Healthcare | $88.76 | 2019-2021 | |
| Boston Scientific Corporation | $75.49 | 2020-2025 | Clinical Trial Product |
| Nevro Corp. | $70.73 | 2021-2024 | Senza |
| Radius Health, INC. | $59.77 | 2024-2025 | Tymlos |
| Ossur Americas, INC. | $53.28 | 2025 | |
| Abbott Laboratories | $52.98 | 2022-2025 | Eterna |
| Portola Pharmaceuticals, LLC | $50.27 | 2019-2020 | |
| Medtronic USA, INC. | $44.85 | 2019-2020 | |
| Lemaitre Vascular, INC. | $39.42 | 2022-2025 | Anastoclip Gc 8cm (Medium) |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $37.64 | 2019-2020 | |
| Philips North America LLC | $32.45 | 2019 | |
| Lundbeck LLC | $31.39 | 2025 | Vyepti |
| Vertex Pharmaceuticals Incorporated | $31.01 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.30 | 2024 | Hyqvia |
| Averitas Pharma INC. | $25.49 | 2025 | Qutenza |
| Kls-Martin L.P. | $22.50 | 2023 | |
| Arbor Pharmaceuticals, INC. | $22.23 | 2021 | |
| Amgen INC. | $21.22 | 2025 | Uplizna |
| Piramal Critical Care | $19.27 | 2024 | |
| Csl Behring | $19.07 | 2019 | |
| Penumbra, INC. | $18.72 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $18.64 | 2024 | Nuedexta |
| Scilex Pharmaceuticals INC. | $16.87 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.82 | 2024 | Relistor |
| Astrazeneca Pharmaceuticals LP | $14.75 | 2022 | |
| Davol INC. | $13.71 | 2020 | |
| Avanir Pharmaceuticals, INC. | $13.17 | 2022 | |
| Alexion Pharmaceuticals, INC. | $13.15 | 2021 | |
| Flowonix Medical Incorporated | $12.77 | 2019 | |
| Pfizer INC. | $12.49 | 2019 | |
| Stimwave Technologies Incorporated | $11.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ankit Gulati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.